DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
Cannabis News Mix: June 2026 Law Enforcement and Industry Updates
This cannabis news mix reviews six articles from June 2026 covering law enforcement encounters, synthetic cannabinoid toxicity, and cannabis industry developments. Dr. Caplan provides clinical commentary on regulatory fragmentation and public safety…
In the Mix: 1 More Article — May 26, 2026
In the Mix — Last 24 HoursMay 26, 2026. 1 article reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #15Morgan City police, St. Mary deputies make synthetic cannabinoid, heroin arrestsThis article details…
In the Mix: 1 More Article — May 21, 2026
In the Mix — Last 24 HoursMay 21, 2026. 1 article reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #6Cienfuegos Court sentences four accused of drug trafficking to prison in a "exemplary" trialThis…
Mouse Study Finds Synthetic Cannabinoid Reduces Blood Flow in Fetal Brain, But Human Relevance Remains Unclear
Both acute and multiple dosing paradigms showed significantly reduced fetal brain microvasculature perfusion compared to vehicle controls… reductions in fetal brain vasculature during cerebrovascular and neural development may substantially affect…
Analytical Challenges and Emerging Detection Strategies of Synthetic Cannabinoids in Horse Doping Control.
Synthetic cannabinoids (SCs) were originally synthesized to advance the understanding of the endocannabinoid system, facilitate disease research, and support...
Synthetic cannabinoids in Mayotte over a year in time and space: an example of high-frequency evolution of market.
Researchers used synthetic cannabinoid wastewater monitoring surveillance to track market evolution in Mayotte over one year. The environmental monitoring approach revealed rapid changes in synthetic cannabinoid composition and geographic distribution,…
Acute toxicity of ADB-CHMINACA – a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome.
A new case series reveals that synthetic cannabinoid toxicity emergency treatment protocols are urgently needed as ADB-CHMINACA causes rapid-onset seizures and encephalopathy. Emergency physicians document severe neurologic complications occurring within…
Call for tighter regulations around synthetic cannabis – RTE
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Synthetic CannabinoidsToxicologyPatient…
